TMCnet - World's Largest Communications and Technology Community



Research and Markets: Metastatic Prostate Cancer - Pipeline Review, H1 2014: 9 Companies and 16 Drugs Profiled
[May 12, 2014]

Research and Markets: Metastatic Prostate Cancer - Pipeline Review, H1 2014: 9 Companies and 16 Drugs Profiled

DUBLIN --(Business Wire)--

Research and Markets ( has announced the addition of the "Metastatic Prostate Cancer - Pipeline Review, H1 2014" report to their offering.

This report provides comprehensive information on the therapeutic development for Metastatic Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Prostate Cancer and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Reasons to bu

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Metastatic Prostate Cancer
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Metastatic Prostate Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies Mentioned:

  • AbbVie Inc.
  • Actinium Pharmaceuticals, Inc.
  • Agonox
  • Camurus AB
  • Colby Pharmaceutical Company
  • Fountain Biopharma Inc.
  • MEI Pharma, Inc.
  • OXiGENE, Inc.
  • Progenics Pharmaceuticals, Inc.

Drug Profiles:

  • cabazitaxel
  • pracinostat
  • leuprolide acetate
  • LU-901
  • veliparib
  • Engineered Autologous T Cells + [cyclophosphamide]
  • MEDI-6469
  • CPC (News - Alert)-410
  • Actimab-P
  • Peptide to Inhibit MT1 MMP for Autoimmune Disorders, Inflammation and Oncology
  • MIP-1095
  • FB-704A
  • Ceramide Analogs
  • KGP-94
  • Vaccine For Oncolytic Newcastle Disease Virus
  • Glutathione Disulfide Liposomal

For more information visit

[ Back To's Homepage ]

Technology Marketing Corporation

35 Nutmeg Drive Suite 340, Trumbull, Connecticut 06611 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments:
Comments about this site:


© 2017 Technology Marketing Corporation. All rights reserved | Privacy Policy